Q-omics provides the consensus-scored CALHM3 profile across patient tissues and cancer cell-line models. CALHM3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, CALHM3 is differentially expressed in 10, with the highest sampling consensus in BRCA. Additionally, CALHM3 RNA expression shows 9,982 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, BRCA, and THYM as cancer lineages where CALHM3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CALHM3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CALHM3 survival associations across molecular data types. CALHM3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CALHM3 RNA expression–survival associations across cancer types. High CALHM3 expression shows unfavorable associations in CHOL, LIHC, LUAD and UVM, but favorable associations in UCS and SKCM. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify UCS as the clearest survival context for CALHM3 RNA expression.
This table summarizes CALHM3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CALHM3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CALHM3 shows higher tumor expression in BRCA, LUAD, STAD, COAD, HNSC and PAAD. The BRCA box plot shows higher CALHM3 RNA expression in tumor versus normal tissue (log2 FC = +0.104, t-test p < 0.001).
This table shows molecular features associated with CALHM3 in patient tissues and cancer cell lines. In patient samples, CALHM3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CALHM3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
